Autifony Therapeutics initiates recruitment into schizophrenia clinical trial for first-in-class drug

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced the start of a Phase Ib biomarker study of the effect of AUT00206, a first-in-class Kv3 ion channel modulator, on patients with schizophrenia.

Read More